Ticagrelor as an alternative in clopidogrel-associated neutropenia

Rahman Shah, Leigh Anne Keough, Astrid Belalcazar-Portacio, K Ramanathan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aspirin in combination with platelet P2Y12 receptor blocker has become the mainstay antiplatelet treatment strategy for the prevention of stent thrombosis. Ticlopidine was the first widely used P2Y12 receptor blockers, but clopidogrel has mostly replaced the use of ticlopidine due to its more favorable adverse event profile on bone marrow. However, when clopidogrel induced bone marrow toxicity occurs, little is known about the efficacy and safety of alternative treatments, and thus, in these cases, medical decisions may be very difficult. We report a case of clopidogrel-induced severe neutropenia in a patient treated with coronary stent and safety of alternative treatment with ticagrelor.

Original languageEnglish (US)
Pages (from-to)80-82
Number of pages3
JournalPlatelets
Volume26
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

clopidogrel
Neutropenia
Ticlopidine
Stents
Bone Marrow
Safety
Aspirin
Thrombosis
Therapeutics
Blood Platelets
Ticagrelor

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Ticagrelor as an alternative in clopidogrel-associated neutropenia. / Shah, Rahman; Keough, Leigh Anne; Belalcazar-Portacio, Astrid; Ramanathan, K.

In: Platelets, Vol. 26, No. 1, 01.01.2015, p. 80-82.

Research output: Contribution to journalArticle

Shah, Rahman ; Keough, Leigh Anne ; Belalcazar-Portacio, Astrid ; Ramanathan, K. / Ticagrelor as an alternative in clopidogrel-associated neutropenia. In: Platelets. 2015 ; Vol. 26, No. 1. pp. 80-82.
@article{901e2312f59a41d4927221f5510b9311,
title = "Ticagrelor as an alternative in clopidogrel-associated neutropenia",
abstract = "Aspirin in combination with platelet P2Y12 receptor blocker has become the mainstay antiplatelet treatment strategy for the prevention of stent thrombosis. Ticlopidine was the first widely used P2Y12 receptor blockers, but clopidogrel has mostly replaced the use of ticlopidine due to its more favorable adverse event profile on bone marrow. However, when clopidogrel induced bone marrow toxicity occurs, little is known about the efficacy and safety of alternative treatments, and thus, in these cases, medical decisions may be very difficult. We report a case of clopidogrel-induced severe neutropenia in a patient treated with coronary stent and safety of alternative treatment with ticagrelor.",
author = "Rahman Shah and Keough, {Leigh Anne} and Astrid Belalcazar-Portacio and K Ramanathan",
year = "2015",
month = "1",
day = "1",
doi = "10.3109/09537104.2013.867427",
language = "English (US)",
volume = "26",
pages = "80--82",
journal = "Platelets",
issn = "0953-7104",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Ticagrelor as an alternative in clopidogrel-associated neutropenia

AU - Shah, Rahman

AU - Keough, Leigh Anne

AU - Belalcazar-Portacio, Astrid

AU - Ramanathan, K

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Aspirin in combination with platelet P2Y12 receptor blocker has become the mainstay antiplatelet treatment strategy for the prevention of stent thrombosis. Ticlopidine was the first widely used P2Y12 receptor blockers, but clopidogrel has mostly replaced the use of ticlopidine due to its more favorable adverse event profile on bone marrow. However, when clopidogrel induced bone marrow toxicity occurs, little is known about the efficacy and safety of alternative treatments, and thus, in these cases, medical decisions may be very difficult. We report a case of clopidogrel-induced severe neutropenia in a patient treated with coronary stent and safety of alternative treatment with ticagrelor.

AB - Aspirin in combination with platelet P2Y12 receptor blocker has become the mainstay antiplatelet treatment strategy for the prevention of stent thrombosis. Ticlopidine was the first widely used P2Y12 receptor blockers, but clopidogrel has mostly replaced the use of ticlopidine due to its more favorable adverse event profile on bone marrow. However, when clopidogrel induced bone marrow toxicity occurs, little is known about the efficacy and safety of alternative treatments, and thus, in these cases, medical decisions may be very difficult. We report a case of clopidogrel-induced severe neutropenia in a patient treated with coronary stent and safety of alternative treatment with ticagrelor.

UR - http://www.scopus.com/inward/record.url?scp=84921452413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921452413&partnerID=8YFLogxK

U2 - 10.3109/09537104.2013.867427

DO - 10.3109/09537104.2013.867427

M3 - Article

C2 - 24433137

AN - SCOPUS:84921452413

VL - 26

SP - 80

EP - 82

JO - Platelets

JF - Platelets

SN - 0953-7104

IS - 1

ER -